ReviewThe Journal of antibiotics2019
Engineering nucleoside antibiotics toward the development of novel antimicrobial agents.
Review in The Journal of antibiotics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Discovery of novel uridine-based chitin synthase inhibitors: Design, synthesis and structure-activity relationships.Pest management science · 2026Article
- Antibacterial mechanism and in vivo efficacy of cladribine against carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2026Article
- Biochemical Characterization of an Arabinoside Monophosphate Specific 5'-Nucleotidase-like Enzyme fromBiomolecules · 2024Article
- Deciphering the Antibacterial Mechanisms of 5-Fluorouracil inAntibiotics (Basel, Switzerland) · 2024Article
- Nucleoside Analogs: A Review of Its Source and Separation Processes.Molecules (Basel, Switzerland) · 2023Review
- Factors driving the halophyte rhizosphere bacterial communities in coastal salt marshes.Frontiers in microbiology · 2023Article
- Molecular mechanism of mureidomycin biosynthesis activated by introduction of an exogenous regulatory gene ssaA into Streptomyces roseosporus.Science China. Life sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a major threat for public health worldwide. Novel antimicrobial drugs are urgently needed to combat the growing prevalence of antimicrobial resistance. Nucleoside antibiotics represent a unique class of microbial natural products with distinctive structural features and diverse biological activities. We herein summarize recent findings on the biosynthesis of representative nucleoside antibiotics, and highlight recent advances in the discovery and rational generation of nucleoside antibiotics for the development of novel antimicrobial agents.
Indexed as
Identifiers
31501499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.